Blanca Homet Moreno
Merck & Co., Inc., Rahway, NJ, USA (United States) · 178 works · 16,367 citations · h-index 38
Top works
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
- Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
- 1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study